The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Gillies Hunter since 2023.
This trader's CIK number is 1868997.
At the time of last reporting, Gillies Hunter was the CHIEF MEDICAL OFFICER of Aerovate Therapeutics, Inc.. (stock ticker symbol AVTE).
Also see all insider trading activities at Aerovate Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2024 | AVTE | 0 | $0 | 46,975 | $1,151,188 | 46,975 | $94,325 |
| 2023 | AVTE | 0 | $0 | 21,280 | $415,684 | 21,280 | $37,075 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-06-13 | AVTE | Option Ex | 6,000 | 2.14 | 12,840 |
| 2024-06-13 | AVTE | Sale | 6,000 | 24.50 | 147,000 |
| 2024-05-17 | AVTE | Option Ex | 4,000 | 2.14 | 8,560 |
| 2024-05-17 | AVTE | Sale | 4,000 | 21.46 | 85,852 |
| 2024-04-17 | AVTE | Sale | 4,000 | 22.81 | 91,256 |
| 2024-04-17 | AVTE | Option Ex | 4,000 | 1.74 | 6,960 |
| 2024-03-28 | AVTE | Option Ex | 9,000 | 2.14 | 19,260 |
| 2024-03-28 | AVTE | Sale | 9,000 | 29.50 | 265,500 |
| 2024-03-18 | AVTE | Sale | 7,000 | 26.11 | 182,756 |
| 2024-03-18 | AVTE | Option Ex | 7,000 | 1.94 | 13,580 |
| 2024-03-07 | AVTE | Option Ex | 8,975 | 2.14 | 19,206 |
| 2024-03-07 | AVTE | Sale | 8,975 | 24.50 | 219,887 |
| 2024-02-23 | AVTE | Option Ex | 511 | 1.74 | 889 |
| 2024-02-23 | AVTE | Sale | 511 | 19.50 | 9,964 |
| 2024-02-20 | AVTE | Option Ex | 3,489 | 1.74 | 6,070 |
| 2024-02-20 | AVTE | Sale | 3,489 | 20.34 | 70,973 |
| 2024-01-17 | AVTE | Option Ex | 4,000 | 1.74 | 6,960 |
| 2024-01-17 | AVTE | Sale | 4,000 | 19.50 | 78,000 |
| 2023-12-27 | AVTE | Sale | 125 | 24.50 | 3,062 |
| 2023-12-27 | AVTE | Option Ex | 125 | 2.14 | 267 |
| 2023-12-20 | AVTE | Sale | 4,000 | 19.50 | 78,000 |
| 2023-12-13 | AVTE | Option Ex | 4,000 | 1.74 | 6,960 |
| 2023-12-13 | AVTE | Sale | 2,103 | 19.50 | 41,008 |
| 2023-12-14 | AVTE | Option Ex | 9,897 | 1.74 | 17,220 |
| 2023-12-13 | AVTE | Option Ex | 2,103 | 1.74 | 3,659 |
| 2023-12-14 | AVTE | Sale | 9,897 | 19.50 | 192,991 |
| 2023-05-19 | AVTE | Option Ex | 65 | 1.74 | 113 |
| 2023-05-19 | AVTE | Sale | 65 | 19.50 | 1,267 |
| 2023-05-17 | AVTE | Option Ex | 1,090 | 1.74 | 1,896 |
| 2023-05-17 | AVTE | Sale | 1,090 | 19.59 | 21,356 |
| 2023-04-21 | AVTE | Option Ex | 4,000 | 1.74 | 6,960 |
| 2023-04-21 | AVTE | Sale | 4,000 | 19.50 | 78,000 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Gillies Hunter (CHIEF MEDICAL OFFICER of Aerovate Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.